Receptor News and Research

RSS

New Astra-Zeneca B.1.351 vaccine AZD2816 strongly immunogenic against multiple SARS-CoV-2 variants of concern

A new study, released on the bioRxiv* preprint server, supports the efficacy of the wildtype ChAdOx1 nCoV-19 (AZD1222) vaccine against B.1.351, B.1.617.1 and B.1.617.2, while showing that a booster dose of vaccine based on the B.1.351 spike induces further increase in antibody titers.

11 Jun 2021

Scientists detect delayed and reduced antibody responses after BioNTech/Pfizer COVID-19 vaccination in older adults

Researchers at the U.S. Centers for Disease Control and Prevention (CDC) detected delayed and reduced antibody and T cell responses after immunization with BNT162b2 or the Pfizer-BioNTech COVID-19 vaccine in older adults compared with healthcare workers in Germany.

11 Jun 2021

Statins associated with reduced COVID-19 mortality and decreased need for ventilator support

Statins are medications widely used in the management of cardiovascular diseases and metabolic syndrome. Statins help lower serum lipids by blocking HMG-CoA reductase (3-hydroxy-3-methyl-glutaryl-coenzyme A reductase), the rate-limiting enzyme of cholesterol biosynthesis.

11 Jun 2021

Nanobodies from nanomice and llamas show potent neutralizing activity against SARS-CoV-2 variants

While several COVID-19 vaccines have been approved to date, the constant evolution of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) receptor-binding domain (RBD) has challenged the efficacy of these vaccines.

11 Jun 2021

Cross-sectional study explores differences in biomarkers in fulminant and non-fulminant COVID-19 myocarditis

Researchers from the US recently conducted a study to examine the clinical course and echocardiographic and lab testing across clinically defined fulminant and non-fulminant COVID-19 myocarditis. This study is published on the preprint server, medRxiv.*

11 Jun 2021

Macrophages can aid tumor growth by distracting cancer-killing CD8+ T cells

A Ludwig Cancer Research study adds to growing evidence that immune cells known as macrophages inhabiting the body cavities that house our vital organs can aid tumor growth by distracting the immune system's cancer-killing CD8+ T cells.

11 Jun 2021

Shark vNAR antibodies inhibit SARS-CoV-2 variants in vitro

Researchers in the UK and Austria have identified a novel class of antibodies that is highly effective at neutralizing the original strain of severe acute respiratory syndrome (SARS-CoV-2) and maintaining blocking activity against certain viral variants that have emerged.

10 Jun 2021

The longevity of SARS-CoV-2 antibodies and their cross-neutralization against variants of concern

In a new study by researchers in the UK, the activity of neutralizing antibodies collected from the sera of individuals that contracted COVID-19 during the first wave of the pandemic is tested against variants of concern the B.1.1.7 (or UK) variant and the B.1.351 (or South African) variant, demonstrating somewhat reduced potency of neutralization towards these strains.

10 Jun 2021

Bovine-derived polyclonal antibodies exhibit high efficacy in neutralizing SARS-CoV-2 variants

A team of scientists in Estonia has recently evaluated the therapeutic/prophylactic efficacy of anti-SARS-CoV-2 polyclonal antibodies derived from the colostrum of immunized cows.

10 Jun 2021

Could the COVID-19 vaccination rollout protect against future coronavirus outbreaks?

A new study suggests that the rollout of vaccines against the COVID-19 pandemic may be significant not only in preventing infections by SARS-CoV-2 but other endemic and pandemic-potential coronaviruses (CoVs) as well.

10 Jun 2021

DNA on-off switches for SARS-CoV-2 host receptor as potential therapeutic targets

Researchers in the United States and Canada have identified DNA on/off “switches” within the angiotensin-converting enzyme 2 (ACE2) gene that may control the expression of this host cell receptor before, during and after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

9 Jun 2021

Smoking and vaping increase ACE2 levels and virus spike binding in airway epithelium

A new bioRxiv preprint attempts to make some sense of why certain people experience more severe forms of COVID-19 as compared to others by pointing to the increase in virus binding that occurs in the presence of smoking or vaping.

9 Jun 2021

Researchers review the therapeutic potential of resveratrol nasal formulations in COVID-19

In a recently published article in the journal Frontiers in Immunology, scientists have reviewed the existing literature on antiviral and anti-inflammatory efficacy of resveratrol-based inhaled formulations in preventing SARS-CoV-2 infection and reducing COVID-19 severity.

9 Jun 2021

SARS-CoV-2 immunity persists for up to 11 months after natural infection

The study, published in the Journal of Infectious Diseases, determined how circulating antibody levels change after being infected with SARS-CoV-2.

8 Jun 2021

Antihistamines might be effective in long-COVID

A team of scientists from the United Kingdom has recently revealed the therapeutic benefits of histamine receptor antagonists in reducing long-term symptoms of coronavirus disease 2019 (COVID-19). They have also indicated that T cell immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection vary between asymptomatic COVID-19 and long-COVID.

8 Jun 2021

How SARS-CoV-2 variant B.1.1.7 adapted to evade innate immunity

Researchers in the United States and the UK have conducted a study showing how the B.1.1.7 (Alpha) lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) adapted to suppress host innate immune responses in lung epithelial cells.

8 Jun 2021

Researchers identify a novel host-directed therapeutic approach to COVID-19

Researchers in the UK have demonstrated the potential of modulating the expression of angiotensin-converting enzyme 2 (ACE2) as a novel host-directed therapeutic approach to protecting against coronavirus disease 2019 (COVID-19).

8 Jun 2021

MIT researchers develop a molecular assay to detect sub-picomolar levels of the SARS-CoV-2's receptor-binding domain

A team of researchers at MIT has developed a molecular assay to detect sub-picomolar levels of the SARS-CoV-2’s spike protein receptor-binding domain (S-RBD) using computationally validated peptide beacons in a single-step detection through the production of a fluorescence signal.

8 Jun 2021

Cell-to-cell contact helps in spreading SARS-CoV-2, finds study

People aren’t the only ones who should be social distancing — new research shows our cells need to as well. Researchers from Ohio State University in Columbus, Ohio, USA, used in-culture techniques to confirm SARS-CoV-2 transmission via cell-to-cell contact.

8 Jun 2021

What lessons have we learned over a year into the COVID-19 pandemic?

One of the pressing questions scientists are currently trying to answer is whether the current vaccines will remain effective against the emerging SARS-CoV-2 variants of concern. A new piece of research has been published in the journal Biomedicines, which discusses the knowledge we have gained thus far and the questions that researchers should address in future work.

8 Jun 2021

Receptor News and Research

New Astra-Zeneca B.1.351 vaccine AZD2816 strongly immunogenic against multiple SARS-CoV-2 variants of concern

Scientists detect delayed and reduced antibody responses after BioNTech/Pfizer COVID-19 vaccination in older adults

Statins associated with reduced COVID-19 mortality and decreased need for ventilator support

Nanobodies from nanomice and llamas show potent neutralizing activity against SARS-CoV-2 variants

Cross-sectional study explores differences in biomarkers in fulminant and non-fulminant COVID-19 myocarditis

Macrophages can aid tumor growth by distracting cancer-killing CD8+ T cells

Shark vNAR antibodies inhibit SARS-CoV-2 variants in vitro

The longevity of SARS-CoV-2 antibodies and their cross-neutralization against variants of concern

Bovine-derived polyclonal antibodies exhibit high efficacy in neutralizing SARS-CoV-2 variants

Could the COVID-19 vaccination rollout protect against future coronavirus outbreaks?

DNA on-off switches for SARS-CoV-2 host receptor as potential therapeutic targets

Smoking and vaping increase ACE2 levels and virus spike binding in airway epithelium

Researchers review the therapeutic potential of resveratrol nasal formulations in COVID-19

SARS-CoV-2 immunity persists for up to 11 months after natural infection

Antihistamines might be effective in long-COVID

How SARS-CoV-2 variant B.1.1.7 adapted to evade innate immunity

Researchers identify a novel host-directed therapeutic approach to COVID-19

MIT researchers develop a molecular assay to detect sub-picomolar levels of the SARS-CoV-2's receptor-binding domain

Cell-to-cell contact helps in spreading SARS-CoV-2, finds study

What lessons have we learned over a year into the COVID-19 pandemic?

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News